Literature DB >> 30770596

Abnormal α-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility.

V Donadio1, K Doppler2, A Incensi1, A Kuzkina2, A Janzen3, G Mayer3, J Volkmann2, G Rizzo1, E Antelmi1, G Plazzi1, C Sommer2, R Liguori1, W H Oertel3.   

Abstract

BACKGROUND AND
PURPOSE: Visualization of phosphorylated α-synuclein at serine 129 (p-syn) in skin nerves is a promising test for the in vivo diagnosis of synucleinopathies. Here the aim was to establish the intra- and inter-laboratory reproducibility of measurement of intraneural p-syn immunoreactivity in two laboratories with major expertise (Würzburg and Bologna).
METHODS: In total, 43 patients affected by Parkinson's disease (PD 21 patients), dementia with Lewy bodies (DLB 1), rapid eye movement sleep behaviour disorder (RBD 11), multiple system atrophy (MSA-P 4) and small fibre neuropathy (SFN 6) were enrolled. Skin biopsy was performed at the C7 paravertebral spine region and distal skin sites (thigh or leg). The analysis was standardized in both laboratories and carried out blinded on a single skin section double stained with antibodies to p-syn and the pan-axonal marker protein gene product 9.5. Fifty skin sections were randomly selected for the analysis: 25 from C7 and 25 from distal sites. Differently classified sections were re-evaluated to understand the reasons for the discrepancy.
RESULTS: The intra-laboratory analysis showed an excellent reproducibility both in Würzburg (concordance of classification 100% of sections; K = 1; P < 0.001) and Bologna (96% of sections; K = 0.92; P < 0.001). Inter-laboratory analysis showed reproducibility in 45 sections (90%; K = 0.8; P < 0.001) and a different classification in five sections, which was mainly due to fragmented skin samples or weak fluorescent signals.
CONCLUSIONS: Analysis of p-syn showed excellent inter- and intra-laboratory reproducibility supporting the reliability of this technique. The few ascertained discordances were important to further improve the standardization of this technique. © European Academy of Neurology 2019.

Entities:  

Keywords:  Parkinson disease; REM sleep behaviour disorder; multiple system atrophy; skin biopsy; α-synuclein deposits

Year:  2019        PMID: 30770596     DOI: 10.1111/ene.13939

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  17 in total

Review 1.  Skin nerve α-synuclein deposits in Parkinson's disease and other synucleinopathies: a review.

Authors:  Vincenzo Donadio
Journal:  Clin Auton Res       Date:  2018-11-30       Impact factor: 4.435

Review 2.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

3.  Blinded RT-QuIC Analysis of α-Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients.

Authors:  Sireesha Manne; Naveen Kondru; Huajun Jin; Geidy E Serrano; Vellareddy Anantharam; Arthi Kanthasamy; Charles H Adler; Thomas G Beach; Anumantha G Kanthasamy
Journal:  Mov Disord       Date:  2020-09-22       Impact factor: 10.338

4.  In Vivo Diagnosis of Synucleinopathies: A Comparative Study of Skin Biopsy and RT-QuIC.

Authors:  Vincenzo Donadio; Zerui Wang; Alex Incensi; Giovanni Rizzo; Enrico Fileccia; Veria Vacchiano; Sabina Capellari; Martina Magnani; Cesa Scaglione; Michelangelo Stanzani Maserati; Patrizia Avoni; Rocco Liguori; Wenquan Zou
Journal:  Neurology       Date:  2021-04-09       Impact factor: 11.800

5.  Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies.

Authors:  Christopher H Gibbons; Roy Freeman; Bailey Bellaire; Charles H Adler; Dan Moore; Todd Levine
Journal:  Biomark Med       Date:  2022-03-11       Impact factor: 2.498

Review 6.  The Challenge and Opportunity to Diagnose Parkinson's Disease in Midlife.

Authors:  Alexander Kilzheimer; Thomas Hentrich; Simone Burkhardt; Julia M Schulze-Hentrich
Journal:  Front Neurol       Date:  2019-12-17       Impact factor: 4.003

Review 7.  Tau and Alpha Synuclein Synergistic Effect in Neurodegenerative Diseases: When the Periphery Is the Core.

Authors:  Elena Vacchi; Alain Kaelin-Lang; Giorgia Melli
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

8.  Trans-synaptic spreading of alpha-synuclein pathology through sensory afferents leads to sensory nerve degeneration and neuropathic pain.

Authors:  Nelson Ferreira; Nádia Pereira Gonçalves; Asad Jan; Nanna Møller Jensen; Amelia van der Laan; Simin Mohseni; Christian Bjerggaard Vægter; Poul Henning Jensen
Journal:  Acta Neuropathol Commun       Date:  2021-02-25       Impact factor: 7.801

Review 9.  Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.

Authors:  Mitchell G Miglis; Charles H Adler; Elena Antelmi; Dario Arnaldi; Luca Baldelli; Bradley F Boeve; Matteo Cesari; Irene Dall'Antonia; Nico J Diederich; Kathrin Doppler; Petr Dušek; Raffaele Ferri; Jean-François Gagnon; Ziv Gan-Or; Wiebke Hermann; Birgit Högl; Michele T Hu; Alex Iranzo; Annette Janzen; Anastasia Kuzkina; Jee-Young Lee; Klaus L Leenders; Simon J G Lewis; Claudio Liguori; Jun Liu; Christine Lo; Kaylena A Ehgoetz Martens; Jiri Nepozitek; Giuseppe Plazzi; Federica Provini; Monica Puligheddu; Michal Rolinski; Jan Rusz; Ambra Stefani; Rebekah L S Summers; Dallah Yoo; Jennifer Zitser; Wolfgang H Oertel
Journal:  Lancet Neurol       Date:  2021-08       Impact factor: 44.182

10.  In vivo distribution of α-synuclein in multiple tissues and biofluids in Parkinson disease.

Authors:  Lana M Chahine; Thomas G Beach; Michael C Brumm; Charles H Adler; Christopher S Coffey; Sherri Mosovsky; Chelsea Caspell-Garcia; Geidy E Serrano; David G Munoz; Charles L White; John F Crary; Danna Jennings; Peggy Taylor; Tatiana Foroud; Vanessa Arnedo; Catherine M Kopil; Lindsey Riley; Kuldip D Dave; Brit Mollenhauer
Journal:  Neurology       Date:  2020-08-03       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.